SynBioBeta Speaker
Jerry McLaughlin
Life Biosciences
CEO
Jerry McLaughlin is chief executive officer and director for Life Biosciences, a clinical-stage biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. He has more than 30 years of biopharmaceutical experience, spanning drug discovery, clinical development, and global commercialization. Jerry has contributed to the approval and launch of more than a dozen FDA-approved medicines and has led multiple exits. Most recently, he served as President and CEO of Neos Therapeutics. Previously, he was president and CEO of AgeneBio, a clinical-stage biopharma focused on neurological and psychiatric diseases. He also served in senior management roles at NuPathe, Endo, and Merck & Co. Inc.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Jerry
This Year
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
